Abstract
A number of neurodegenerative diseases, as Parkinson, prion, and Alzheimers diseases, has been directly associated with altered conformations of certain peptides or proteins that assemble to form highly organized aggregates, also called amyloid fibers. Glycosaminoglycans have shown to play important roles on fibrils formation, stability and resistance to proteolysis. This manuscript reviews from basic concepts on the biochemistry and biology of glycosaminoglycans to their implications in neurodegeneration with particular emphasis in pathologic protein aggregation. Prion protein, Aβ42, Tau, and α-synuclein, are all proteins that can interact with glycosaminoglycans. We document here how these interactions may modify protein conformation, aggregation kinetics, and fibers stabilization with important consequences in disease. We also raise questions which answers may make advance the understanding of the implication of GAGs in neurodegeneration.
Keywords: Glycosaminoglycans, heparan sulfate, protein aggregation, prion, Aβ42, tau, α-synuclein, neurodegeneration, amyloid fibers, synuclein, Parkinson disease, Alzheimer's disease, polypeptide aggregation, histopathological method, heparin binding proteins
Current Protein & Peptide Science
Title: Glycosaminoglycans, Protein Aggregation and Neurodegeneration
Volume: 12 Issue: 3
Author(s): Dulce Papy-Garcia, Morin Christophe, Huynh Minh Bao, Sineriz Fernando, Sissoeff Ludmilla, Sepulveda Diaz Julia Elisa and Raisman-Vozari Rita
Affiliation:
Keywords: Glycosaminoglycans, heparan sulfate, protein aggregation, prion, Aβ42, tau, α-synuclein, neurodegeneration, amyloid fibers, synuclein, Parkinson disease, Alzheimer's disease, polypeptide aggregation, histopathological method, heparin binding proteins
Abstract: A number of neurodegenerative diseases, as Parkinson, prion, and Alzheimers diseases, has been directly associated with altered conformations of certain peptides or proteins that assemble to form highly organized aggregates, also called amyloid fibers. Glycosaminoglycans have shown to play important roles on fibrils formation, stability and resistance to proteolysis. This manuscript reviews from basic concepts on the biochemistry and biology of glycosaminoglycans to their implications in neurodegeneration with particular emphasis in pathologic protein aggregation. Prion protein, Aβ42, Tau, and α-synuclein, are all proteins that can interact with glycosaminoglycans. We document here how these interactions may modify protein conformation, aggregation kinetics, and fibers stabilization with important consequences in disease. We also raise questions which answers may make advance the understanding of the implication of GAGs in neurodegeneration.
Export Options
About this article
Cite this article as:
Papy-Garcia Dulce, Christophe Morin, Minh Bao Huynh, Fernando Sineriz, Ludmilla Sissoeff, Diaz Julia Elisa Sepulveda and Rita Raisman-Vozari, Glycosaminoglycans, Protein Aggregation and Neurodegeneration, Current Protein & Peptide Science 2011; 12 (3) . https://dx.doi.org/10.2174/138920311795860188
DOI https://dx.doi.org/10.2174/138920311795860188 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Amyloid-Degrading Enzymes as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Nitric Oxide and Dopamine Neurons. Implications for Parkinsons Disease
Current Medicinal Chemistry - Central Nervous System Agents A Current Review of Cypermethrin-Induced Neurotoxicity and Nigrostriatal Dopaminergic Neurodegeneration
Current Neuropharmacology Epigenetics, Depression and Antidepressant Treatment
Current Pharmaceutical Design The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry Mitophagy in Neurodegeneration: An Opportunity for Therapy?
Current Drug Targets Role of Autophagy in Alzheimer’s Disease
Current Enzyme Inhibition Conformational Changes of Prion Protein and Nucleic Acid Arising from their Interaction and Relation of the Altered Structures in Causing Prion Disease
Mini-Reviews in Medicinal Chemistry Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design Role of Lipid Rafts/Caveolae in the Anticancer Effect of Endocannabinoids
Mini-Reviews in Medicinal Chemistry Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design Contribution of Inflammatory Processes to Nerve Cell Toxicity by Bilirubin and Efficacy of Potential Therapeutic Agents
Current Pharmaceutical Design P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Current Cancer Drug Targets Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design
Current Topics in Medicinal Chemistry Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Current Progress in Sample Preparation for Two-Dimensional Electrophoresis in Proteomics
Current Proteomics Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry An Overview of the α4β1 Integrin and the Potential Therapeutic Role of its Antagonists
Current Medicinal Chemistry